The structural and biochemical impacts of monomerizing human acetylcholinesterase.

Printer-friendly versionPrinter-friendly versionPDF versionPDF version
TitleThe structural and biochemical impacts of monomerizing human acetylcholinesterase.
Publication TypeJournal Article
Year of Publication2019
AuthorsBester, SM, Adipietro, KA, Funk, VL, Myslinski, JM, Keul, ND, Cheung, J, Wilder, PT, Wood, ZA, Weber, DJ, Height, JJ, Pegan, SD
JournalProtein Sci
Date Published2019 06
KeywordsAcetylcholinesterase, Binding Sites, Humans, Models, Molecular, Mutation, Protein Conformation

Serving a critical role in neurotransmission, human acetylcholinesterase (hAChE) is the target of organophosphate nerve agents. Hence, there is an active interest in studying the mechanism of inhibition and recovery of enzymatic activity, which could lead to better countermeasures against nerve agents. As hAChE is found in different oligomeric assemblies, certain approaches to studying it have been problematic. Herein, we examine the biochemical and structural impact of monomerizing hAChE by using two mutations: L380R/F535K. The activities of monomeric hAChE L380R/F535K and dimeric hAChE were determined to be comparable utilizing a modified Ellman's assay. To investigate the influence of subunit-subunit interactions on the structure of hAChE, a 2.1 Å X-ray crystallographic structure was determined. Apart from minor shifts along the dimer interface, the overall structure of the hAChE L380R/F535K mutant is similar to that of dimeric hAChE. To probe whether the plasticity of the active site was overtly impacted by monomerizing hAChE, the kinetic constants of (P ) - VX (ethyl({2-[bis(propan-2-yl)amino]ethyl}sulfanyl)(methyl)phosphinate) inhibition and subsequent rescue of hAChE L380R/F535K activity with HI-6 (1-(2'-hydroxyiminomethyl-1'-pyridinium)-3-(4'-carbamoyl-1-pyridinium)) were determined and found to be comparable to those of dimeric hAChE. Thus, hAChE L380R/F535K could be used as a substitute for dimeric hAChE when experimentally probing the ability of the hAChE active site to accommodate future nerve agent threats or judge the ability of new therapeutics to access the active site.

Alternate JournalProtein Sci
PubMed ID30993792
PubMed Central IDPMC6856767
Grant ListT32 AR007592 / AR / NIAMS NIH HHS / United States